Aseptika Activ8rlives Recognised for Global Innovation with Digital Healthcare Award

HUNTINGDON, U.K. - Feb. 9, 2015 - PRLog -- The Global Award has been developed as a comprehensive assessment of the most innovative companies working in the digital and mobile healthcare sector.

The Global Digital Health 100 Award (http://www.thejournalofmhealth.com/#!The-Journal-of-mHealth-Announces-the-2014-Global-Digital-Health-100-Recognising-the-Most-Innovative-Digital-Companies-in-Healthcare/cuhk/8C07B55F-084F-4C3E-BD3D-4A63343372FA) acknowledges the significant work and innovation being carried out in this field by pioneering organisations from around the globe, reflecting the importance of mobile and digital solutions. The Award selection process was undertaken by the editorial team at The Journal of mHealth based on ten different quantitative and qualitative evaluation criteria including: disruptive impact, proof of concept, technology innovation, social value, execution of strategy, and industry integration. An initial list of 1,500 offerings, innovations and companies were considered before the selection of the final 100.

The Journal of mHealth editorial team has: “selected the 100 companies that demonstrate true innovation and the opportunity to disrupt the delivery of healthcare at scale. The selection criteria meant that we were able to truly consider companies based upon innovation, comparing start-up offerings alongside established and larger organisations.”

Commenting on the most recent accolade, Kevin A. Auton Ph.D., Founder and Managing Director of Aseptika Limited said:

“To be recognised as a part of this global list of innovative and pioneering organisations working in mobile and digital healthcare is a tremendous honour. This tops off an exciting and dynamic year in 2014 for Aseptika. It is a testament to the hard work and dedication of staff, clinical and technology partners and the SBRI Healthcare team, without whom we would not have been able to develop our solutions, which have enabled patients and their carers to learn from their data and to better self-manage this long-term condition. We need a new generation of simple tools to help us, our families and the network of our clinical supporters, achieve these goals and reduce the growing pressure on our NHS and social care.”

- Ends -

About Aseptika Limited (Activ8rlives)

Aseptika Limited is a healthcare company developing and marketing an integrated suite of self-monitoring devices and services under the Activ8rlives brand. We are developing integrated systems which can be used by laypeople and their healthcare service providers to better self-manage (http://www.activ8rlives.com/solutions/self-monitoring-and...) long-term health conditions through self-monitoring.

The Company’s goal is to provide everyone with tools (and the understanding of how to apply them) so that most of us can keep healthy and well for most of the time. Self-management through self-monitoring is the motivation driving what we do.

Activ8rlives is unusual in that we are device agnostic, incorporating sensors and monitors ranging from consumer accessories to in vitro diagnostics (IVDs) with a focus on respiratory disease. All data is held together and can be cross analysed in the Cloud to provide forecasts and learning for the user and clinician.

The Company gained a patent in 2013 protecting the invention of a test for biomarkers (http://www.activ8rlives.com/about/news-and-events/news/20...) of Pseudomonas aeruginosa in the sputum of patients, which can be used to detect the on-set of an exacerbation and profile the efficacy of antibiotic treatment for each patient.

Aseptika won first place in a competition earlier in 2014 to reward the most “Promising eHealth EU SME”eHealth solution 2014 (http://www.activ8rlives.com/about/news-and-events/news/20...)developed by an early-stage European SME. The 2014 Competition was organized by TICBioMed and had the endorsement of the Health and Wellbeing Unit of DG CONNECT of the European Commission. The judges commended Aseptika for the integrated approach it was taking in the support of patients with long-term respiratory disease (http://www.activ8rlives.com/solutions/clinical-trials/), providing the platform to self-manage their illness through self-monitoring. Central to the Company’s “hospital-at-home” concept, is a test in which the patient measures the level of virulence of the bacteria living in their lungs which from time to time, flare into a full and repeated chest infections.

Aseptika was a shortlisted finalist for the Cambridge News Top Innovations 2014 (http://www.cambridge-news.co.uk/Innovations-2014/story-22802672-detail/story.html) and AXA PPP Health Tech & You (http://tr.axa-ppp.co.uk/do?B1D6C55B52E4CA5F29BAC297AFEC96616BEED2ADFC11507352CB0B093683219668A1A1FDC5BE1F9AAFCFBA515D62693465C0057B22D451DBCA5F71EBBA9990A9) Awards. Winner of the Discovery Start-up 2014 Competition (http://www.cambridgewireless.co.uk/news/article/default.aspx?objid=47697) run by Cambridge Wireless and Winner of the Hunts Post Huntingdonshire Business Innovation Awards 2014 (http://www.huntsbusinessawards.co.uk/). The entries were for our respiratory hospital-at-home solution and biomarker test, which is currently running as the SENSOR (http://www.activ8rlives.com/sensor) clinical trial with a group of volunteer patients that suffer from COPD or severe Asthma in the Portsmouth area.

For more information on Aseptika Ltd, Activ8rlives and products, please visit: www.Activ8rlives.com

Activ8rlives, Activ8rlives.com and BuddyWOTCH are trademarks of Aseptika Ltd.

For press information, please contact:

Jessica Auton, Marketing Director, Aseptika Ltd (Activ8rlives)

jessica.auton@aseptika.com

Direct +44 (0)1480 352 821

Mobile +44 (0)7455 922 122